Idelalisib immune-related toxicity is associated with improved treatment response. Wagner-Johnston ND, Sharman J, Furman RR, Salles G, et al. Leuk Lymphoma 2021;62:2915-2920.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wagner-Johnston ND, Sharman J, Furman RR, Salles G, et al. Idelalisib immune-related toxicity is associated with improved treatment response. Leuk Lymphoma 2021;62:2915-2920.
PMID: 34319205